Search Results
Your search for early matches 10467 pages
Showing 10101 - 10150ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
U.S. Lung Cancer Rates Vary by Subtype, Sex, Race/Ethnicity, and Age
A new analysis confirms that U.S. lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in Cancer, the findings provide a more accurate picture of the state of lung cancer in the...
Improvements in Overall Survival in Trilateral Retinoblastoma Due to Improved Chemotherapy and Earlier Detection
In a systematic review and meta-analysis reported in The Lancet Oncology, de Jong et al found a dramatic improvement in overall survival among children with trilateral retinoblastoma since 1995, reflecting increased use of conventional and high-dose chemotherapy with stem cell rescue in pineal and...
Phase II Study Supports Further Investigation of Neoadjuvant Carboplatin in Stage II to III Triple-Negative Breast Cancer
In the phase II Cancer and Leukemia Group B (CALGB) 40603/Alliance trial reported in the Journal of Clinical Oncology, Sikov et al found that the addition of carboplatin or bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rate in...
Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...
Increases Seen in Use of Digital Mammography and Related Screening Costs in Medicare Population, but No Increase in Early Detection
In a study of use of breast cancer screening modalities in the Medicare population reported in the Journal of the National Cancer Institute, Killelea et al found significant increases in use of digital image acquisition and computer-aided detection and cost of screening, but no increase in rate of...
No Difference in Complication Rates or Hospital Stay With Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer
In a trial reported in The New England Journal of Medicine, Bochner et al found no difference in complication rates or length of hospital stay with robot-assisted laparoscopic radical cystectomy vs open surgery in patients with bladder cancer. Blood loss was greater and procedure time shorter with...
Improved Prognosis Seen in Older Women With Mammography-Detected Breast Cancer
Mammography-detected breast cancer is associated with a shift to earlier stage diagnosis in older women, subsequently reducing the rate of more advanced, difficult-to-treat cases, according to a new study by Malmgren et al published in the journal Radiology. The findings lend support to regular...
Renowned Pathologist Emmanuel Farber, MD, PhD, Dies
Cancer research lost a pioneer on August 3, 2014, with the passing of Emmanuel Farber, MD, PhD, a renowned pathologist who made fundamental contributions to our understanding of chemical carcinogenesis. Dr. Farber’s studies in experimental pathology demonstrated that chemical carcinogens are...
Blood and Saliva Tests Help Predict Recurrence of HPV-Related Oral Cancer
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other...
PIK3CA Mutation Does Not Predict Outcome in Patients With Luminal Breast Cancer Receiving Endocrine Therapy
In a study reported in the Journal of Clinical Oncology, Sabine et al found that PIK3CA mutation was not an independent predictor of distant relapse-free survival among postmenopausal women with estrogen receptor–positive breast cancer receiving endocrine therapy in the TEAM (Exemestane...
Acupuncture Provides Significant Quality-of-Life Improvements Among Breast Cancer Patients With Aromatase Inhibitor–Related Joint Pain
Use of electroacupuncture—a form of acupuncture where a small electric current is passed between pairs of acupuncture needles—produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain...
Study Helps Compare Risks of Endoscopic vs Surgical Resection for Early Esophageal Cancer
A new study published in the Journal of the National Cancer Institute by researchers at Northwestern Medicine shed new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. Merkow et al found that the...
First Surveillance Imaging at 6 Months May Be Adequate for Most Patients After Treatment for Early-Stage Non‒Small Cell Lung Cancer
Early surveillance imaging (< 6 months) after stereotactic body radiation therapy for early-stage non–small cell lung cancer (NSCLC) seems to be of limited benefit, resulting in definitive intervention in only 3% of patients, according to the findings of a study in Practical Radiation...
FDA Expands Approved Use of Ibrutinib for Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL) who carry deletions of the short arm of chromosome 17, which are associated with poor responses to standard treatment for CLL. Ibrutinib...
Adaptive Intensity-Modulated Radiation Therapy Strategy May Ensure Adequate Target Coverage in Patients With Cervical Cancer
A novel, dosimetry-triggered, adaptive intensity-modulated radiation therapy strategy for patients with cervical cancer may minimize the risk of target underdosing in the setting of very small margins and substantial interfractional motion, according to a study by Lim et al in the International...
Antipain Agent Shrinks Oral Cancers, Sparing Healthy Tissue
Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. The findings by...
Study Suggests That Primary Androgen-Deprivation Therapy Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer
Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...
Metabolic Enzyme Stops Growth of Most Common Type of Kidney Cancer
In an analysis of metabolites in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. The new study, published in Nature by Simon et al, demonstrated that an enzyme called FBP1,...
No Disease-Free Survival Benefit of Adjuvant Zoledronic Acid in High-Risk Patients With Early Breast Cancer
In the open-label phase III AZURE trial reported in The Lancet Oncology, Coleman et al found that adjuvant zoledronic acid treatment in patients with high-risk early-stage breast cancer provided no overall disease-free survival benefit. A reduction in bone metastases was observed, and women who...
Noninvasive Image Texture Analysis May Provide Tumor Heterogeneity Information With Prognostic Potential in NSCLC
Noninvasive quantitative computed tomography–based texture analysis can accurately differentiate the presence of a KRAS mutation from pan–wild-type non–small cell lung cancer (NSCLC), based on the results of a study in PLOS ONE. Weiss et al reported that this tumor heterogeneity...
Testicular Cancer Rates Are on the Rise in Young Hispanic Americans
A new analysis has found that rates of testicular cancer have been rising dramatically in recent years among young Hispanic American men, but not among their non-Hispanic counterparts. Published early online in Cancer, the findings indicate that greater awareness is needed concerning the increasing ...
Total-Body Photography and Sequential Digital Dermoscopy Assist in Early Diagnosis of Primary Melanoma in High-Risk Individuals
In a study intended to help define optimal screening in individuals at high risk of melanoma, Moloney et al evaluated use of full-body examinations every 6 months along with dermoscopy and total-body photography for all patients and sequential digital dermoscopy imaging as indicated. The study,...
Brain Tumor Invasion Along Blood Vessels May Lead to New Cancer Treatments, Preclinical Study Suggests
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, preclinical study published in Nature Communications indicated. The finding by Watkins et al could ultimately lead to new ways to bring about the ...
Fox Chase Cancer Center Researchers Recommend Updating the Staging Criteria for Breast Cancers With Skin Involvement
Invasive breast cancers with skin involvement, regardless of size or lymph node involvement, are automatically classified as stage III locally advanced tumors, which suggests that they are a relatively serious form of cancer with poor survival. In a study published in the Journal of the American...
French Phase III Trial Shows No Benefit of Neoadjuvant Chemoradiation in Stage I and II Esophageal Cancer
The effect of neoadjuvant chemoradiation therapy in early-stage esophageal cancer is not clear. In the phase III FFCD 9901 trial reported in the Journal of Clinical Oncology, Mariette et al found that neoadjuvant chemoradiation including fluorouracil (5-FU) and cisplatin did not improve R0...
Frailty Predicts Noninitiation but Not Discontinuation of Adjuvant Hormonal Therapy in Older Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Sheppard et al found that frailty was a significant predictor of not starting adjuvant hormonal therapy in breast cancer patients aged ≥ 65 years, but was not predictive of discontinuation of treatment. Study Details The study was...
FDA Grants Breakthrough Therapy Designation to Investigational Chimeric Antigen Receptor Therapy for Relapsed/Refractory ALL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The Breakthrough Therapy filing...
Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones
A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...
HIV-Infected People With Early-Stage Cancers Are Up to Four Times More Likely to Go Untreated for Cancer
HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a large retrospective study from researchers in Penn Medicine’s Abramson Cancer Center and the National Cancer Institute (NCI). The ...
No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer
In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...
Early Evidence Suggests Proton Therapy May Offer Safe, Long-Term Treatment for Hodgkin Lymphoma
Despite some success in treating patients with Hodgkin lymphoma, many patients may experience late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. A study by Hoppe et al from the University of Florida Proton Therapy Institute...
HERA Trial 8-Year Follow-up Shows Low Rate of Trastuzumab-Associated Cardiac Dysfunction
In a study reported in Journal of Clinical Oncology, Azambuja et al found low rates of trastuzumab (Herceptin)-related cardiac dysfunction over a median of 8 years of follow-up in the HERceptin Adjuvant (HERA) trial. The majority of patients with cardiac dysfunction achieved acute recovery. Study...
Racial Disparities in Sentinel Lymph Node Biopsy in Women With Breast Cancer
A study by Black et al from The University of Texas MD Anderson Cancer Center, Houston, found that the use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity...
Combined Index Predicts Early Multiple Myeloma Progression-Related Death in Patients Receiving Front-Line Autologous Stem Cell Transplantation
In a European study reported in the Journal of Clinical Oncology, Moreau et al developed and validated a combined index for prognosis in patients with multiple myeloma treated with front-line autologous stem cell transplantation. The index, consisting of high lactate dehydrogenase (LDH) level,...
Study Reveals Long-Term Benefits With Prone Hypofractionated Radiation Therapy and a Concurrent Boost in Early-Stage Breast Cancer
Prone accelerated intensity-modulated radiation therapy with a concomitant boost produced excellent local tumor control and cosmesis while sparing normal tissues in women with early-stage breast cancer, according to the 5-year study results reported by Osa et al in the International Journal of...
Phase III Trial of Adding Figitumumab to Chemotherapy in Advanced Nonadenocarcinoma NSCLC Stopped Early for Futility and Increased Harm
In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal...
Palliative Resection of Primary Tumor May Improve Survival in Patients With Metastatic Colorectal Cancer
Palliative resection of the primary tumor was associated with a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic colorectal cancer, according to the results of a study reported in the Annals of Surgical Oncology. Gresham et al noted...
Mammography Has Led to Fewer Late-Stage Breast Cancers, Study Finds
In the past 30 years, since mammography was introduced, late-stage breast cancer incidence has decreased by 37%, a new study published in Cancer has found. The analysis by Helvie et al took into account an observed underlying trend of increased breast cancer incidence present since the 1940s....
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Starting Palliative Care Support for Family Caregivers at the Time of Cancer Diagnosis Improves Quality of Life
Introducing a palliative care support program for caregivers of patients with advanced cancer at or near the time patients are diagnosed provides greater benefits than delayed palliative care services, according to results of the ENABLE III study reported at the 2014 ASCO Annual Meeting in Chicago...
ASCO 2014: Ipilimumab/Nivolumab Combination Achieves Long-Term Survival for Patients With Advanced Melanoma
Concurrent treatment with ipilimumab (Yervoy) and nivolumab resulted in a 2-year survival rate of 79% for patients with advanced melanoma. “While this is a small trial, that is very impressive 2-year survival data,” noted Mario Sznol, MD, at a press briefing on progress in immunotherapy ...
Early Change in Chemotherapy Based on Elevated Circulating Tumor Cells Does Not Improve Outcome in Metastatic Breast Cancer
Elevated circulating tumor cells are associated with poor prognosis in metastatic breast cancer. In the phase III Southwest Oncology Group (SWOG) S0500 trial reported in the Journal of Clinical Oncology, Smerage et al assessed whether changing chemotherapy after one cycle of first-line treatment in ...
ASCO 2014: PD-1–Targeting Antibody Pembrolizumab Produces Long-Term Responses in Patients With Metastatic Melanoma
Findings from a large phase I study of 411 patients with advanced melanoma show that the PD-1–targeting antibody pembrolizumab (MK-3475) produced responses in 34% of patients, including 28% of patients whose disease progressed on prior treatment with ipilimumab (Yervoy). Among those who...
Adjuvant! Online Performs Poorly in Older Patients With Breast Cancer in Dutch Study
In a Dutch population-based study reported in The Lancet Oncology, de Glas et al found that the Adjuvant! Online prediction tool performed poorly in older patients with early-stage breast cancer, significantly overestimating or underestimating overall survival depending on comorbidity...
ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer
A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen
A joint analysis of two phase III trials demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers. Exemestane plus ovarian...
ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...
ASCO 2014: Patients With Metastatic Colon Cancer Respond to New Combination Therapy, Phase IB Study Shows
In a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 3516), researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vemurafenib (Zelboraf), cetuximab (Erbitux),...
